TYRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tyra Biosciences Inc (TYRA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst ratings, a promising drug pipeline with multiple Phase 2 readouts expected in 2026, and a SwingMax entry signal. Despite insider selling and lack of immediate financial growth, the long-term potential of its lead drug candidate and positive sentiment from analysts outweigh the negatives.
The MACD is negative and contracting, indicating a bearish trend, but RSI at 55.234 is neutral. Key resistance is at 37.512, which the pre-market price of 37.08 is approaching, suggesting potential upward momentum. Moving averages are converging, showing no strong trend direction.
Strong analyst ratings with multiple 'Buy' recommendations and price targets ranging from $50 to $59.
Promising drug pipeline with dabogratinib showing potential in multiple indications.
SwingMax entry signal on 2026-04-21, indicating a buy-low opportunity.
Pre-market price increase of 1.06%, showing positive sentiment.
Insider selling has increased by 100.98% over the last month.
Lack of revenue growth and negative net income, though losses have narrowed YoY.
No recent news or congress trading data to provide additional momentum.
In Q4 2025, Tyra Biosciences reported no revenue growth (0% YoY). Net income improved by 32.31% YoY but remains negative at -$33.83 million. EPS also improved by 32.56% YoY to -0.57. The company is still in its development phase, with no gross margin.
Analysts are overwhelmingly positive, with multiple 'Buy' ratings and price targets ranging from $50 to $59.62. Guggenheim, Canaccord, Piper Sandler, and others highlight the potential of dabogratinib as a selective FGFR3 inhibitor with broad therapeutic applications and a clean safety profile.
